STOCK TITAN

MapLight sets up stock offering of up to $100M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. entered into a sales agreement with Leerink Partners LLC under which MapLight may sell voting common stock with an aggregate offering price of up to $100,000,000. Sales, if any, may be made in transactions deemed “at the market offerings.”

Leerink will use commercially reasonable efforts to sell shares based on MapLight’s instructions and is entitled to a commission of up to 3.0% of the aggregate gross sales price per share sold. MapLight is not obligated to sell shares and may suspend offers or terminate the agreement at any time.

Filing Explained

The one-hundred-million-dollar ATM is within the four-hundred-million-dollar shelf, so the stated amount is capacity, not completed dilution.

On November 16, 2026, MapLight Therapeutics reported entering an agreement with Leerink Partners allowing it to sell up to $100,000,000 of voting common stock. The associated Form S-3 was not effective in the supplied shelf record, and this 8-K reports no completed sales. The arrangement therefore creates conditional sale capacity, not an issuance; if shares are sold, the added shares increase the total share count and reduce existing holders’ percentage ownership.

Once effective and with an accompanying prospectus supplement, the broader shelf would allow up to $400,000,000 in securities, with the ATM’s $100,000,000 included in, not added to, that ceiling.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
ATM offering capacity Up to $100,000,000 aggregate offering price Voting common stock MapLight may sell under the sales agreement
Agent commission Up to 3.0% Of the aggregate gross sales price per share sold under the agreement
at the market offerings regulatory
"transactions that are deemed to be “at the market offerings”"
At-the-market offerings are a way for a company to raise cash by selling newly issued shares directly into the open market at the current trading price through a broker, rather than in a single large sale. Think of it like topping up a gas tank a little at a time at whatever the pump price is; it gives the company flexibility to raise money when conditions are favorable but can increase the number of shares outstanding and dilute existing investors, and frequent or large sales can put downward pressure on the stock price.
aggregate offering price financial
"having an aggregate offering price of up to $100,000,000"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much stock may MPLT sell through the ATM offering?

MapLight may sell voting common stock with an aggregate offering price of up to $100,000,000 under the sales agreement.

What commission is Leerink Partners entitled to receive for MPLT’s ATM sales?

Leerink Partners LLC is entitled to a commission of up to 3.0% of the aggregate gross sales price per share sold under the agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001770069 0001770069 2026-11-16 2026-11-16
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

MapLight Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-42914   83-2163243

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices)

Registrant’s telephone number, including area code: (617) 984-6300

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange

on which registered

Voting Common Stock, $0.0001 par value per share   MPLT   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01

Entry Into A Material Definitive Agreement.

On November 16, 2026, MapLight Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its voting common stock, par value $0.0001 per share (“Common Stock”), through or to the Agent (the “ATM Offering”). The ATM Shares will be offered and sold pursuant to a Registration Statement on Form S-3 filed by the Company on November 16, 2026 (the “Registration Statement”) and the prospectus related to the ATM Offering that forms a part of such Registration Statement (the “ATM Prospectus”). Pursuant to the ATM Prospectus, the Company may sell Common Stock having an aggregate offering price of up to $100,000,000.

Subject to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon the Company’s instructions. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a commission of up to 3.0% of the aggregate gross sales price per share sold under the Agreement.

Sales of the ATM Shares, if any, under the Agreement may be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the ATM Shares and may at any time suspend offers under the Agreement or terminate the Agreement.

This Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the ATM Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

This description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.

 

Item 9.01

Financial Statement and Exhibits.

(d) Exhibits

 

Exhibit

Number

   Exhibit Description
10.1    Sales Agreement, dated November 16, 2026, by and between the Company and Leerink Partners LLC (incorporated herein by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 (File No. 333-300071) filed with the SEC on November 16, 2026).
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MapLight Therapeutics, Inc.
Dated: November 16, 2026     By:  

/s/ Christopher A. Kroeger

      Christopher A. Kroeger, M.D.
      Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Keep reading